Ultragenyx Pharmaceutical Inc.
NASDAQ:RAREBiotechnology
+$0.81 today
- Market cap
- $1.81B
- Beta
- 0.38
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$6.06
Volume 5.16M
Average 1.81M
RARE EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Ultragenyx Pharmaceutical Inc.NASDAQ: RARE
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$155M, compared with -$126.44M a year earlier. Trailing-twelve-month EBITDA was -$503.35M.
Context
- EBITDA amounted to 70.4% of revenue in FY2025, down 13.3 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 14 analysts of -$18.52M (+96.1%) for the fiscal year ending Dec 2026, a step up from the -1.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$155M-54.7% QoQ
- Last fiscal yearDec 2025
- -$474M-1.1% YoY
- LTMMar 2026
- -$503.35M-11.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -22.6% | -5.9% | +16.6 pp |
| 1 year | -1.1% | +96.1% | +97.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (474M) USD
- Year-over-year change
- -1.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (474M) | -1.1% |
| FY2024 | 2024-12-31 | (469M) | +9.2% |
| FY2023 | 2023-12-31 | (516.45M) | +19.4% |
| FY2022 | 2022-12-31 | (640.49M) | -56.1% |
| FY2021 | 2021-12-31 | (410.32M) | — |
EBITDA vs competitors
How RARE compares with its peers on the latest reported figures
- RARE's LTM Mar 2026 EBITDA of -$503.35M is the 9th highest of the 11 companies compared; the peer median is -$146.28M.
- Its year-over-year change of -11.9% is the 8th highest of 11, against a peer median of +5.7%.
- EBITDA amounts to 75.2% of revenue for RARE, versus a peer median of 185.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $173.52M | -79.4% | — | 17.2% | |
| LTM Mar 2026 | $73.43M | +298.8% | — | 505.0% | |
| LTM Mar 2026 | -$39.29M | +13.4% | — | 7858.4% | |
| LTM Mar 2026 | -$95.72M | +32.5% | — | 120.0% | |
| LTM Mar 2026 | -$129.14M | +6.4% | — | 713.8% | |
| LTM Mar 2026 | -$163.43M | +3.9% | — | 185.2% | |
| LTM Mar 2026 | -$194.47M | +21.0% | — | — | |
| LTM Mar 2026 | -$229.35M | -87.3% | — | 261.2% | |
| LTM Mar 2026 | -$503.35M | -11.9% | — | 75.2% | |
| LTM Jun 2026 | -$611.26M | +5.0% | — | 85.7% | |
| LTM Sep 2026 | -$81.69B | -10676.6% | +29.2% | 8.0% | |
| Peer median (excluding RARE) | -$146.28M | +5.7% | +29.2% | 185.2% | |
Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 351.41M | 363.33M | 434.25M | 560.23M | 673M |
| Cost of Revenue | 16.01M | 28.32M | 45.21M | 76.73M | 109M |
| Gross Profit | 335.4M | 335.01M | 389.04M | 483.5M | 564M |
| Gross Margin | 95.4% | 92.2% | 89.6% | 86.3% | 83.8% |
| Research & Development | 497.15M | 705.79M | 648.45M | 697.87M | 750M |
| Selling, General & Admin | 219.98M | 278.14M | 309.8M | 321.61M | 349M |
| Operating Expenses | 717.14M | 983.93M | 958.25M | 1.02B | 1.1B |
| Depreciation & Amortization | 13.24M | 18.22M | 26.01M | 35.54M | 35M |
| EBITDA | (410.32M) | (640.49M) | (516.45M) | (469M) | (474M) |
| EBITDA Margin | -116.8% | -176.3% | -118.9% | -83.7% | -70.4% |
| Operating Income | (381.74M) | (648.92M) | (569.21M) | (535.97M) | (535M) |
| Operating Margin | -108.6% | -178.6% | -131.1% | -95.7% | -79.5% |
| Interest Income | 1.93M | 11.07M | 26.69M | 36.51M | 25M |
| Interest Expense | 29.42M | 43.02M | 66M | 63.04M | 62M |
| Other Income / Expenses | (71.24M) | (52.81M) | (39.26M) | (31.61M) | (36M) |
| Income Before Tax | (452.98M) | (701.73M) | (608.46M) | (567.59M) | (571M) |
| Pre-Tax Margin | -128.9% | -193.1% | -140.1% | -101.3% | -84.8% |
| Income Tax Expense | 1.04M | 5.7M | (1.83M) | 1.6M | 4M |
| Net Income | (454.03M) | (707.42M) | (606.64M) | (569.18M) | (575M) |
| Net Margin | -129.2% | -194.7% | -139.7% | -101.6% | -85.4% |
| EPS (Basic) | (6.70) | (10.12) | (8.25) | (6.29) | (5.83) |
| EPS (Diluted) | (6.70) | (10.12) | (8.25) | (6.29) | (5.83) |
| Weighted Avg Shares | 67.8M | 69.91M | 73.54M | 90.54M | 98.6M |
| Weighted Avg Shares (Diluted) | 67.8M | 69.91M | 73.54M | 90.54M | 98.6M |
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
Intrinsic Alpha fair value
Locked
Current Price
$17.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.